Terns Pharmaceuticals Inc (TERN) Stock Price, Quote & News

Company Profile

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phas...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 525 5535

Fax: 650 275 4254

Website: www.ternspharma.com

Address:

1065 East Hillsdale Boulevard, Suite 100, Foster City, United States

StockRadars Jul. 12 at 9:22 PM

$TERN wish i held my shares from 6$ lol

0 · Reply

StockMktGuru Jul. 11 at 5:09 PM

$ALT It is what it is, current SP means nothing. Check where $VKTX and $TERN have been in the past $3.X at sometime for them would have been god sent. Frustrating but hang in here, things can change in a hurry.

0 · Reply

BIOTECH_GURU Jul. 9 at 3:23 AM

$TERN $ALMS $PRME $ALT $CAPR Alright folks. You saw AlMS, TERN and CApR MAKE WILD RUNS IN 8 MONTHS. get ready for the next runs. $PRME Just formed a golden cross. Won huge legal battle which had a lot of overhang and drove price from upper teens to below $3. Continues to be the highest asymetric play in gene editing as the technology is the cleanest. In human proof of concept is already proven and published. This will make those with high conviction big gains. $ALT all the waiting will be paying off within the next 6 months. $CAPR dropped back down to let me buy the dip. 60 dollars PT. Nfa Gltya.

0 · Reply

Layne_Thomas_Staley Jul. 7 at 4:22 PM

$GANX $MRK Bought $TERN after the company pivoted away from crowded GLP weight loss land into a groundbreaking cancer drug. In microcap bio, you CANNOT BE LATE TO THE GAME. Even if a company develops a superior product, it's not like you can walk into a store and buy it off a shelf. The bottleneck is BULLISH FOR A FIRST MOVER.

0 · Reply

Layne_Thomas_Staley Jul. 7 at 4:18 PM

$GANX Nice recovery so far... Microcap bio can be brutal. It also can be your $TERN for the generational wealth

0 · Reply

shopno Jun. 30 at 12:16 AM

$SLS +1. everyone should check $TERN fabulous 2,600% ride from $2 to $53 just in 1 year! TERN is very relevant, as it's for CML and got acquired for $6.7B with early stage data. BO premium was almost absent telling everyone that it's NOT WISE to get late on-board, if you look for big reward at BO. Some of my calls, for example, are > 10x just within a few months! Check the historical $TERN price here -- on 4/8/2025 price was $2.05, and on 3/30/2026 price was $52.88! $SLS to meet & possibly beat it with blowout GPS readout! https://www.macrotrends.net/stocks/charts/TERN/terns-pharmaceuticals/stock-price-history

0 · Reply

BioRich Jun. 16 at 9:11 PM

$CRMD Quick look over at the gainers for today and I saw this grouping. How many Buyouts or deals did we have in this group? Good lord. Will $CRMD be added to that distinguished list? I think so. For fun, the 2 picks above the screen grab was $AKRO, one below was $NUVL. $TERN? $VRNA? Some real life changes in here. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

1 · Reply

BIOTECH_GURU Jun. 16 at 1:16 PM

$SLS blah blah blah. Bears came out agains $CAPR at $7.X Came out against $REPL at $3.X Came out agains $TERN at $7.X The science will dictate where we go with $SLS. The harder they short the bigger the potential to launch 10-20x

1 · Reply

BIOTECH_GURU Jun. 9 at 4:06 AM

$ALMS $TERN $GPCR smart people follow the money.

0 · Reply

amessagefromtheodd May. 30 at 11:02 AM

$ALMS $CAPR $SLS $TERN There is more to see 💎 🙌🏿

1 · Reply

Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

MRK

Apr 27, 2026, 8:05 AM EDT - 2 months ago

Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

Apr 24, 2026, 6:45 AM EDT - 2 months ago

Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.

MRK

Apr 15, 2026, 7:59 AM EDT - 3 months ago

Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders?

SLNO WSR

Apr 7, 2026, 9:00 AM EDT - 3 months ago

Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

MRK

Apr 2, 2026, 4:05 PM EDT - 3 months ago

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Mar 30, 2026, 7:00 AM EDT - 3 months ago

Terns Pharmaceuticals Annual report: Q4 2025

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Terns Pharmaceuticals Transcript: M&A announcement

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Terns Pharmaceuticals Slides: M&A announcement

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Terns Pharmaceuticals Press release: M&A announcement

Mar 25, 2026, 7:14 AM EDT - 3 months ago

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

MRK

Mar 25, 2026, 6:51 AM EDT - 3 months ago

Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma

MRK

Mar 25, 2026, 6:49 AM EDT - 3 months ago

Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns

MRK

Mar 25, 2026, 6:48 AM EDT - 3 months ago

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

MRK

Mar 24, 2026, 9:14 PM EDT - 3 months ago

Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports

MRK

Mar 11, 2026, 9:00 AM EDT - 4 months ago

Terns Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026

Mar 9, 2026, 1:40 PM EDT - 4 months ago

Terns Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 3:50 PM EST - 4 months ago

Terns Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 4:05 PM EST - 4 months ago

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Jan 22, 2026, 10:26 AM EST - 6 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 12, 2026, 6:45 PM EST - 6 months ago

Terns Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 PM EST - 6 months ago

Terns Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 6 months ago

Terns Pharmaceuticals Slides: Corporate presentation

Jan 7, 2026, 4:05 PM EST - 6 months ago

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 6:31 PM EST - 7 months ago

Terns CEO Amy Burroughs talks cancer drug trial win

Dec 11, 2025, 4:05 PM EST - 7 months ago

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 9, 2025, 11:30 PM EST - 7 months ago

Terns Announces Pricing of Upsized $650 Million Public Offering

Dec 9, 2025, 3:31 PM EST - 7 months ago

Cancer Study Buoys These Small Biotechs

ACLX LEGN

Dec 9, 2025, 6:12 AM EST - 7 months ago

Terns Announces Proposed Public Offering

Dec 8, 2025, 4:30 PM EST - 7 months ago

Terns Pharmaceuticals Transcript: Study Update

Dec 8, 2025, 4:30 PM EST - 7 months ago

Terns Pharmaceuticals Press release: Study Update

Dec 8, 2025, 4:30 PM EST - 7 months ago

Terns Pharmaceuticals Slides: Study Update

$Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting$

Dec 8, 2025, 2:45 PM EST - 7 months ago

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

Nov 17, 2025, 11:30 AM EST - 8 months ago

Terns Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 14, 2025, 4:05 PM EST - 8 months ago

Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

Nov 10, 2025, 4:05 PM EST - 8 months ago

Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 10, 2025, 4:00 PM EST - 8 months ago

Terns Pharmaceuticals Quarterly report: Q3 2025

Nov 10, 2025, 4:00 PM EST - 8 months ago

Terns Pharmaceuticals Earnings release: Q3 2025

$Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting$

Nov 3, 2025, 9:05 AM EST - 9 months ago

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

Oct 21, 2025, 4:56 PM EDT - 9 months ago

Terns Pharma ends obesity drug program after mid-stage trial data

Oct 21, 2025, 4:05 PM EDT - 9 months ago

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity

Sep 3, 2025, 4:30 PM EDT - 11 months ago

Terns Pharmaceuticals Transcript: Study Update

Sep 3, 2025, 4:30 PM EDT - 11 months ago

Terns Pharmaceuticals Slides: Study Update

Aug 21, 2025, 4:05 PM EDT - 11 months ago

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

Aug 5, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 5, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Quarterly report: Q2 2025

Aug 5, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Earnings release: Q2 2025

Jun 23, 2025, 4:07 PM EDT - 1 year ago

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

Jun 9, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 6, 2025, 7:00 AM EDT - 1 year ago

Terns Pharmaceuticals Slides: Corporate Presentation

Jun 5, 2025, 11:05 AM EDT - 1 year ago

Terns Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 14, 2025, 9:30 AM EDT - 1 year ago

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

May 8, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 8, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Terns Pharmaceuticals Registration statement: Registration Filing

May 7, 2025, 2:30 PM EDT - 1 year ago

Terns Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference 2025

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Terns Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Terns Pharmaceuticals Proxy statement: Proxy Filing

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Mar 20, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Earnings release: Q4 2024

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Annual report: Q4 2024

Mar 4, 2025, 2:30 PM EST - 1 year ago

Terns Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

Feb 25, 2025, 8:05 AM EST - 1 year ago

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

Feb 24, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

Feb 20, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Feb 12, 2025, 4:00 PM EST - 1 year ago

Terns Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 5, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Jan 15, 2025, 7:30 PM EST - 1 year ago

Terns Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

Terns Pharmaceuticals Slides: FY 2025

Jan 8, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 1:18 PM EST - 1 year ago

Terns's stock soars as analysts cheer leukemia data — and predict more gains

Dec 3, 2024, 8:01 AM EST - 1 year ago

Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial

Dec 3, 2024, 8:00 AM EST - 1 year ago

Terns Pharmaceuticals Transcript: Study Result

Dec 3, 2024, 8:00 AM EST - 1 year ago

Terns Pharmaceuticals Press release: Study Result

Dec 3, 2024, 8:00 AM EST - 1 year ago

Terns Pharmaceuticals Slides: Study Result

Nov 19, 2024, 12:00 PM EST - 1 year ago

Terns Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

Nov 15, 2024, 11:19 AM EST - 1 year ago

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

AMGN LLY NVO VKTX

Nov 13, 2024, 11:45 AM EST - 1 year ago

Terns Pharmaceuticals Transcript: UBS Global Healthcare Conference 2024

Nov 12, 2024, 9:30 AM EST - 1 year ago

Terns Pharmaceuticals Quarterly report: Q3 2024

Nov 12, 2024, 9:30 AM EST - 1 year ago

Terns Pharmaceuticals Earnings release: Q3 2024

Sep 12, 2024, 7:00 PM EDT - 1 year ago

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

StockRadars Jul. 12 at 9:22 PM

$TERN wish i held my shares from 6$ lol

0 · Reply

StockMktGuru Jul. 11 at 5:09 PM

0 · Reply

BIOTECH_GURU Jul. 9 at 3:23 AM

0 · Reply

Layne_Thomas_Staley Jul. 7 at 4:22 PM

0 · Reply

Layne_Thomas_Staley Jul. 7 at 4:18 PM

$GANX Nice recovery so far... Microcap bio can be brutal. It also can be your $TERN for the generational wealth

0 · Reply

shopno Jun. 30 at 12:16 AM

0 · Reply

BioRich Jun. 16 at 9:11 PM

1 · Reply

BIOTECH_GURU Jun. 16 at 1:16 PM

1 · Reply

BIOTECH_GURU Jun. 9 at 4:06 AM

$ALMS $TERN $GPCR smart people follow the money.

0 · Reply

amessagefromtheodd May. 30 at 11:02 AM

$ALMS $CAPR $SLS $TERN There is more to see 💎 🙌🏿

1 · Reply

Sihttegroftnod May. 30 at 12:58 AM

$ALMS $CAPR $SLS $TERN This! Right here!!

0 · Reply

BIOTECH_GURU May. 30 at 12:48 AM

$SLS they want the retail to sell. They dropped prices for multiple recent biotechs right before the rip. $TERN $CAPR $ALMS Hold the line or regret being Mcpaperhands.

0 · Reply

YouVSYou May. 26 at 1:46 AM

Eli Lilly’s one-time gene editing therapy cut LDL cholesterol by 62% in Phase 1 trial participants, with effects lasting up to 18 months. No serious adverse events reported. $LLY $NVO $HIMS $TERN

0 · Reply

MilsLearning May. 22 at 9:37 AM

$TERN

0 · Reply

BIOTECH_GURU May. 20 at 1:49 PM

$SLS $CAPR $TERN $ALMS $SLS paperhands should be ashamed of selling this anywhere less than $20

1 · Reply

55X_ROI_Q1_2026 May. 15 at 5:29 PM

$SLS - pardon me @Maxamillion5000, i know some are just getting to know... and for anyone interested in MONEY. https://www.reddit.com/r/sellasLifescience/search/?q=aml-mr&cId=057d1aab-2b7d-4bf0-a2d4-c3227af101f8&iId=8d5110f2-0189-40ea-bc04-b363b5cad724 - link for 009 DD. SLS009 is the only Effective Agent for the Most Dire AML Prognosis, AML-MR - Mutations TP53 Asxl1 Runx Ezh2 -- AML that is mutated, often after Chemo from other cancers. SLS009 has direct market Comps $TERN $FTSV both bought for $5B+ based on Lesser PH2B DATA SLS009 Published at ASH.

0 · Reply

judgeyoung2 May. 5 at 5:10 PM

$GEV sold this right after the spin off. sold $TERN at $7 lmao. i just need to not touch things.

1 · Reply

Floridaorange May. 4 at 3:45 PM

$RXRX notice the yearly chart looks like every beatdown SaaS stock? That’s because the market is not accurately valuing or categorizing $RXRX. Miscategorized = mispriced. Earnings this Wed could be the shift. $SMMT $TERN $VKTX

1 · Reply

kubota2323 May. 2 at 2:45 AM

$TERN welp

0 · Reply

kingofking719 Apr. 30 at 6:07 PM

$UAMY $BULL $SOUN $TERN @JarvisProtocols we don't care

1 · Reply

55X_ROI_Q1_2026 Apr. 30 at 4:10 PM

$SLS SLS009 Pristine Safety Profile Durable Efficacy, for the most Dire of AML Mutations, worth more than $TERN and $FTSV You will wish you bought more. We All Will.

0 · Reply

55X_ROI_Q1_2026 Apr. 30 at 3:38 PM

$SLS $MRK $TERN

0 · Reply

Market Cap	6.12B
Revenue (ttm)	0.00
Net Income (ttm)	-96.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	6,347,000
Avg Vol	6,722,514
Day's Range	N/A - N/A
Shares Out	115.52M
Stochastic %K	85%
Beta	-0.37
Analysts	Hold
Price Target	$53.00